A detailed history of Ewa, LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Ewa, LLC holds 16,707 shares of AUTL stock, worth $43,104. This represents 0.02% of its overall portfolio holdings.

Number of Shares
16,707
Previous 17,738 5.81%
Holding current value
$43,104
Previous $76.1 Million 33.92%
% of portfolio
0.02%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$3.38 - $4.69 $3,484 - $4,835
-1,031 Reduced 5.81%
16,707 $50.3 Million
Q2 2024

Jul 24, 2024

SELL
$3.33 - $5.68 $21,851 - $37,272
-6,562 Reduced 27.0%
17,738 $76.1 Million
Q1 2024

May 13, 2024

SELL
$5.39 - $7.29 $7,427 - $10,045
-1,378 Reduced 5.37%
24,300 $97 Million
Q4 2023

Feb 05, 2024

BUY
$2.13 - $6.63 $15,678 - $48,803
7,361 Added 40.19%
25,678 $155 Million
Q3 2023

Nov 14, 2023

BUY
$2.32 - $3.36 $42,495 - $61,545
18,317 New
18,317 $67 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $235M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Ewa, LLC Portfolio

Follow Ewa, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ewa, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ewa, LLC with notifications on news.